Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.

被引：3
|
作者：
Vogelzang, Nicholas J.
Encarnacion, Carlos A.
Cohn, Allen Lee
DiSimone, Christopher
Rasco, Drew W.
Richards, Donald A.
Taylor, Matthew H.
Dutcus, Corina E.
Stepan, Daniel E.
Shumaker, Robert Charles
Guo, Matthew
Schmidt, Emmett V.
Mier, James Walter
机构：
[1] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[2] Texas Oncol, Waco, TX USA
[3] US Oncol, Rocky Mt Canc Ctr, Denver, CO USA
[4] Arizona Onc Assoc, Tucson, AZ USA
[5] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[6] US Oncol Res, Tyler, TX USA
[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[8] Eisai Inc, Woodcliff Lake, NJ USA
[9] Merck & Co Inc, Kenilworth, NJ USA
[10] Dana Farber Harvard Canc Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
    Glen J Weiss
    Jordan Waypa
    Lisa Blaydorn
    Jessica Coats
    Kayla McGahey
    Ashish Sangal
    Jiaxin Niu
    Cynthia A Lynch
    John H Farley
    Vivek Khemka
    British Journal of Cancer, 2017, 117 : 33 - 40
  • [32] Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer
    Bauer, Smadar
    Saad, Akram
    Greenhouse, Inbal
    Rapoport, Anna Ruth
    Shahar, Shir
    Barnatan, Tania
    Satchi-Fainaro, Ronit
    Shapira-Frommer, Ronnie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Pembrolizumab plus enfortumab vedotin in urothelial cancer
    Santoni, Matteo
    Takeshita, Hideki
    Massari, Francesco
    Bamias, Aristotelis
    Cerbone, Linda
    Fiala, Ondrej
    Mollica, Veronica
    Buti, Sebastiano
    Santoni, Angela
    Bellmunt, Joaquim
    NATURE REVIEWS UROLOGY, 2024, 21 (07) : 387 - 388
  • [34] A PHASE II TRIAL OF PEMBROLIZUMAB AND LENVATINIB IN RECURRENT OR PERSISTENT CLEAR CELL CARCINOMA OF THE OVARY
    Lee, Elizabeth
    Tayob, Nabihah
    Rimel, Bj
    Hendrickson, Andrea Wahner
    Nixon, Andrew
    Matulonis, Ursula
    Liu, Joyce
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A238 - A238
  • [35] A phase Ib/II study of cetuximab and pembrolizumab in metastatic colorectal cancer
    Fountzilas, C.
    Mukherjee, S.
    Saltzman, J.
    Bajor, D.
    Muhitch, J.
    Abrams, S.
    Maguire, O.
    Minderman, H.
    Wang, K.
    Hutson, A.
    Hicks, K.
    Ventola, J.
    Kalinski, P.
    Iyer, R.
    Boland, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S140 - S140
  • [36] A Phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
    Ikeda, M.
    Sung, M. W.
    Kudo, M.
    Kobayashi, M.
    Baron, A. D.
    Finn, R. S.
    Kaneko, S.
    Zhu, A. X.
    Kubota, T.
    Kraljevic, S.
    Ishikawa, K.
    Siegel, A. B.
    Kumada, H.
    Okusaka, T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 37 - 37
  • [37] Multicenter phase II trial of pembrolizumab (pembro) in previously-treated metastatic esophageal cancer.
    Enzinger, Peter C.
    McCleary, Nadine Jackson
    Horick, Nora
    Cleary, James M.
    Rubinson, Douglas Adam
    Fitzpatrick, Bridget
    Graham, Christopher
    Clark, Jeffrey W.
    Patel, Anuj K.
    Pectasides, Eirini
    Perez, Kimberly
    Yurgelun, Matthew B.
    Azzoli, Christopher G.
    Enzinger, Andrea Catherine
    Gainor, Justin F.
    Schlechter, Benjamin L.
    Meyerhardt, Jeffrey A.
    Ng, Kimmie
    Bass, Adam Joel
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Combined checkpoint immunotherapy and cytotoxic chemotherapy: Further results from a phase Ib/II trial of pembrolizumab and docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer
    Parikh, Mamta
    Pan, Chong-xian
    Beckett, Laurel
    Li, Yueju
    Robles, Daniel
    DeVisser, Christina
    Lara, Primo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Testicular cancer: No activity of pembrolizumab in phase II trial
    Thoma C.
    Nature Reviews Urology, 2017, 14 (12) : 700 - 700
  • [40] Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC)
    Zhang, Tian
    Staats, Janet S.
    Chan, Cliburn
    Harrison, Michael Roger
    O'Donnell, Peter H.
    Batich, Kristen A.
    Chen, Tianling
    Krejsa, Cecile
    Izumi, Raquel
    George, Daniel J.
    Weinhold, Kent J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345